68 results about "Heparinoid" patented technology

A copolymer comprising (a) one or more pendant group segments and (b) one or more polyol segments, each of said segments being linked to one or more further segments which may be the same or different,wherein said one or more pendant group segments are the same or different and are selected from:(i) siloxane segments;(ii) segments containing phosphoryl choline or a derivative or analogue thereof;(iii) segments containing a di- or trifluoromethyl group;(iv) heparin-like segments containing a group of formula (XII)D-N═N—Ar—SO3−  (XII)wherein D is an aliphatic or aromatic group and Ar—SO3− comprises one or more linked aryl and / or heteroaryl groups, at least one of the aryl and / or heteroaryl groups having an SO3− substituent; and(v) segments containing a group of formula (I)[P]n′-[Lys]n-Lys-[Spacer]-Lys-[Al]x  (I)wherein:[Al] is an inert amino acid;x is 0, 1, 2 or 3;[Spacer] is a fatty acid, amino acid, peptide or PEG;[P]n′-[Lys]n is a dendritic structure formed from n lysine groups and terminating in n′ groups P;n is an integer of from 1 to 15;n′ is zero or an integer of up to 16; andeach P is the same or different and is an amino acid or a peptide having up to 25 amino acids,and wherein at least a part of each of said pendant group segment(s) is on a side chain of the copolymer.The copolymer is useful in the production of implantable devices such as vascular grafts.

Plaster for topical use having an analgesic activity and at the same time being able to re-absorb haematomas, comprising: a substrate layer; an adhesive layer in the form of a hydrogel matrix containing a pharmaceutically acceptable diclofenac salt, heparin or a heparinoid; a protective film which can be removed at the moment of use.

The invention relates to compounds which are polysufated oligosaccharide derivatives having activity as inhibitors of heparan sulfate-binding proteins and inhibitors of the enzyme heparanase; methods for the preparation of the compounds; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and / or antithrombotic treatment, lowering of blood triglyceride levels and inhibition of cardiovascular disease of a mammalian subject.

The present invention aims to provide an agent for promoting HGF production comprising, as an effective ingredient, a disaccharide comprised of an uronic acid residue (wherein an uronic acid means an iduronic acid or a glucuronic acid, and has the same meaning hereinafter) and a glucosamine residue that are connected by α1,4-glycosidic linkage or β1,4-glycosidic linkage, or an oligosaccharide of tri- to hexadeca-saccharides having a structure in which uronic acid residues and glucosamine residues are alternately and repeatedly connected by α1,4-glycosidic linkage or β1,4-glycosidic linkage, wherein at least one hydroxy group of the uronic acid residues and / or the glucosamine residues may be sulfated, alkylated, acylated or aminated, and / or the amino group at position 2 of at least one of the glucosamine residue(s) may be sulfated, alkylated or acylated, or a salt thereof. The agent of the present invention for promoting HGF production is useful to promote healing of damaged tissues or organs of a living body.

The present invention is related to heparin-like compounds characterized by their capacity of inhibiting collagen-induced platelet aggregation in flowing whole blood and their use for prophylactic treatment of arterial thrombosis associated with vascular or microvascular injury and interventions. Said properties are related to a high coupling density of negatively charged heparin or heparin-like glycosaminoglycan molecules, present in multiple heparin or heparin-like glycosaminoglycans as well as in proteoglycans containing said multiple heparin or heparin-like glycosaminoglycans or lower-molecular-weight heparin or heparin-like glycosaminoglycans connected directly or through spacer / linker molecules to globular core molecules. Heparin-like compounds, with said properties are obtainable from mammalian mast cells, by tissue extraction or cell cultivation. The heparin-like compounds of the present invention can also be produced by synthetical, semisynthetical and / or biotechnological methods and they are useful for manufacturing preparations, means and devices for local or topical application in prophylactic treatment of arterial thrombosis and its sequelae.

The invention relates to the technical field of material smashing, and discloses a blockage-free multilevel smasher for processing heparinoid. The blockage-free multilevel smasher comprises a feedinghopper, a multilevel smashing mechanism and a main discharging hole, wherein the multilevel smashing mechanism is in communication with the feeding hopper; the main discharging hole is in communication with the multilevel smashing mechanism; the multilevel smashing mechanism comprises a first-level smashing cavity and a second-level smashing cavity which is positioned below the first-level smashing cavity; a feeding hole A of the first-level smashing cavity is in communication with the feeding hopper; a discharging hole B of the first-level smashing cavity is in communication with a feeding hole C of the second-level smashing cavity; a discharging hole D of the second-level smashing cavity is in communication with the main discharging hole; and a shredder principle is adopted by the first-level smashing cavity. Compared with the prior art, the blockage-free multilevel smasher has the advantages that one smashing cavity is added, the shredder principle is adopted by the first-level smashing cavity, and two cutter shafts are used for driving a cutterhead to rotate towards each other to realize a blockage-free material smashing cavity. The two smashing cavities work simultaneously, large material blocks are smashed with the first-level smashing cavity into small material blocks, and the small material blocks enter the second-level smashing cavity for smashing and filtering througha screen, so that the feeding holes of the smashing cavities are prevented from being blocked, and the machine smashing efficiency is improved.

The invention discloses a preparation method of an extracorporeal circulation anticoagulant modified membrane. The preparation method comprises the following steps: 1, synthesizing carboxylated polysulfone / polyethersulfone; 2, synthesizing apixaban modified polysulfone / polyethersulfone; 3, preparing an apixaban modified polysulfone / polyethersulfone membrane. According to the extracorporeal circulation anticoagulant modified membrane and the preparation method thereof provided by the invention, an Xa factor inhibitor apixaban is grafted to base materials such as polyethersulfone (PES) and polysulfone (PSf), the base materials are modified by the apixaban, and membrane material wall-attached thrombus is efficiently inhibited through signal amplification, so that the membrane has strong anticoagulant and antithrombotic performance. The modification process is simple in synthesis condition, high in controllability and suitable for subsequent industrial large-scale production. According to the novel extracorporeal circulation anticoagulant modified membrane, the steric hindrance effect caused by heparin / heparinoid synthesis is effectively avoided, and meanwhile, the risk of severe bleeding caused by heparin-induced thrombocytopenia (HIT) is reduced.

An improved method for preparing a composition including a heparinoid, a local anesthetic, and a buffer for treatment of a lower urinary tract disease or condition can comprise either: (A) (i) providing a heparinoid in solid form or liquid form; (ii) providing a local anesthetic in solid form or liquid form; (iii) adding a liquid buffer to the heparinoid in solid form or liquid form; (iv) adding the local anesthetic to the mixture of the liquid buffer and the heparinoid; and (v) if necessary, adjusting the pH of the mixture of the liquid buffer, the local anesthetic, and the heparinoid so that a pH is achieved of from about 6.8 to about 8.3 is achieved without precipitation of the local anesthetic; or (B) (i)providing a heparinoid in solid form or liquid form; (ii) providing a local anesthetic in solid form or liquid form; (iii) mixing the heparinoid in solid form or liquid form and the local anesthetic in solid form or liquid form; (iv) adding a liquid buffer to the mixture of the heparinoid and the local anesthetic to form a mixture of liquid buffer, the heparinoid, and the local anesthetic; and (v) if necessary, adjusting the pH of the mixture of the liquid buffer, the local anesthetic, and the heparinoid so that a pH is achieved of from about 7.0 to about 7.8 is achieved without precipitation of the local anesthetic. The invention also encompasses a stable premixed liquid composition that avoids precipitation of the local anesthetic.

The invention discloses a gel containing a heparin-like composition, and belongs to the field of biotechnology. The gel containing the heparin-like composition is characterized by comprising 0.01-30 parts of mucopolysaccharide, 30-90 parts of a matrix material, 0.01-5 parts of a transdermal absorbent, 0.01-5 parts of an antioxidant, 0.01-5 parts of a bacteriostatic agent, 0.01-15 parts of a surfactant and 0.01-5 parts of a preservative. Under a synergistic action of a keratin softening agent and a natural moisturizing agent, the gel containing the heparin-like composition can inhibit the excessive growth of collagen fiber and reduce scar formation; the gel containing the heparin-like composition can retain moisture on the surface of skin to soften the collagen fiber and enhance the elasticity and has an effect of softening a hypertrophic scar.

An object of the present invention is provide a method for sulfating a glycosaminoglycan in a solution of a non-organic solvent. In the present invention, sulfation reaction of a glycosaminoglycan is performed with a sulfating agent in a strongly basic solution of a non-organic solvent. In the present invention, pH of the strongly basic solution is preferably set to be 11.5 or higher. According to the present invention, for example, a glycosaminoglycan having heparin-like anticoagulant activity can be produced from N-acetylheparosan through one-pot procedure. In one embodiment, a sulfated glycosaminoglycan produced by the method of the present invention has a unique disaccharide composition and is expected to be a novel useful material.

The invention discloses a core-shell structured heparinoid microsphere based on graphene oxide grafted urease, and a preparation method and applications of the core-shell structured heparinoid microsphere. According to the preparation method, a graphene oxide two-dimensional nanosheet layer is taken as a base material, immobilizing urease on the surface of the base material by carbodiimide methodso as to obtain a core solution; in-situ cross-linking polymerization is adopted to prepare a heparinoid polymer solution to obtain a shell solution; and reverse-forward phase inversion method is adopted to obtain the core-shell structured heparinoid microsphere. The core-shell structured heparinoid microsphere is capable of removing urea with high efficiency in hemoperfusion, relieving patient pain, and can also be used for dialysate regeneration in hemodialysis, and provide technical support for a wearable artificial kidney.

The invention discloses an application of macromolecular polysaccharide in removing inhalable particles in respiratory tracts. The invention further discloses an atomizing agent for removing the inhalable particles in the respiratory tracts. The atomizing agent comprises the following raw materials: macromolecular polysaccharide and water. The macromolecular polysaccharide is at least one of dextran, hydroxyethyl starch, cellulose, starch, glycogen, hemicellulose, alginic acid, glucosaminoglycan, heparan sulfate, succinylated gelatin, polygeline, chondroitin sulfate and hyaluronic acid. Respiratory tract spray of a macromolecular polysaccharide solution can increase respiratory tract wetness. Meanwhile, the macromolecular polysaccharide can effectively adsorb and wrap inhaled fine particulate matter (PM2.5). Finally, the macromolecular polysaccharide-fine particulate matter adsorption wrappage is pushed to the upper respiratory tract through ciliary movement of bronchial epithelium, and the macromolecular polysaccharide-fine particulate matter adsorption wrappage is discharged out of the body through cough.

Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids.

The invention discloses antithrombotic heparin extracted from short necked clam and a preparation method and application of the antithrombotic heparin. The invention is characterized in that the structural formula of the heparin tetrasaccharide is as shown in (I), and the preparation method comprises the following steps: adding distilled water into short necked clam meat powder to dissolve a sample, regulating the pH value to 7.8-8.2, adding alkaline protease and papain to carryi out enzymolysis to obtain an enzymatic hydrolysate, carrying out enzyme deactivation, centrifuging, and taking a supernatant; transferring the supernatant into a balanced chromatographic column with macroporous ion exchange resin, taking distilled water as a solvent in the column, and combining and collecting elution components of a 1.5 M NaCl solution; concentrating the collected eluted component, adding ethanol, standing, centrifuging, taking a precipitate, alternately washing the precipitate with acetone and ethanol, dissolving the precipitate with water, centrifuging to remove insoluble substances, and repeating the operation for 3-4 times; and finally, dialyzing, and freeze-drying to obtain the antithrombotic heparin product extracted from short necked clam. The invention has the advantages of low bleeding side effect, mild anticoagulation effect and strong fibrinolysis effect.